Partager
Annuaire
Vous êtes ici : Version françaiseAnnuaire

Coordonnées

Centre de Tours 37380 NOUZILLY

Mail
nicolas.azzopardi@univ-tours.fr

Activités / CV

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Tout M, Gagez AL, Leprêtre S, Gouilleux-Gruart V, Azzopardi N, Delmer A, Mercier M, Ysebaert L, Laribi K, Gonzalez H, Paintaud G, Cartron G, Ternant D. Clin Pharmacokinet. 2016 Oct 25.

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D. Clin Pharmacokinet. 2016 Nov;55(11):1381-1394.

Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
Pointreau Y, Azzopardi N, Ternant D, Calais G, Paintaud G. Ther Drug Monit. 2016 Oct;38(5):567-72.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T. Pharmacogenomics. 2015 Dec;16(18):2035-43.

Pharmacokinetics of adalimumab in Crohn's disease.
Ternant D, Karmiris K, Vermeire S, Desvignes C, Azzopardi N, Bejan-Angoulvant T, van Assche G, Paintaud G. Eur J Clin Pharmacol. 2015 Sep;71(9):1155-7.

Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G. MAbs. 2015;7(3):630-7.

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations.
Hervé V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, Duruisseaux M, Fouquenet D, Montharu J, Redini F, Paintaud G, Lemarié E, Cadranel J, Wislez M, Heuzé-Vourc'h N. MAbs. 2014;6(6):1638-48.

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.
Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres C, Herault O, Le Pape A, Diot P, Lemarié E, Paintaud G, Gouilleux-Gruart V, Heuzé-Vourc'h N. J Control Release. 2014 Dec 28;196:344-54.

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies.
Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, Ohresser M, Boisdron-Celle M, Gamelin E, Watier H, Paintaud G, Gouilleux-Gruart V. MAbs. 2013 Jul-Aug;5(4):614-9.

Influence of plasma exchange on rituximab pharmacokinetics.
Azzopardi N, François M, Laurent E, Paintaud G, Birmelé B. Br J Clin Pharmacol. 2013 Sep;76(3):486-8.

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Azzopardi N, Lecomte T, Ternant D, Boisdron-Celle M, Piller F, Morel A, Gouilleux-Gruart V, Vignault-Desvignes C, Watier H, Gamelin E, Paintaud G. Clin Cancer Res. 2011 Oct 1;17(19):6329-37.

The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.
Maillet A, Guilleminault L, Lemarié E, Lerondel S, Azzopardi N, Montharu J, Congy-Jolivet N, Reverdiau P, Legrain B, Parent C, Douvin DH, Hureaux J, Courty Y, De Monte M, Diot P, Paintaud G, Le Pape A, Watier H, Heuzé-Vourc'h N. Pharm Res. 2011 Sep;28(9):2147-56.

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Chu Miow Lin D, Mulleman D, Azzopardi N, Griffoul-Espitalier I, Valat JP, Paintaud G, Goupille P.Scand J Rheumatol. 2010;39(1):97-8.

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab.
Cézé N, Ternant D, Piller F, Degenne D, Azzopardi N, Dorval E, Watier H, Lecomte T, Paintaud G.Ther Drug Monit. 2009 Oct;31(5):597-601.

Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis.
Thariat J, Azzopardi N, Peyrade F, Launay-Vacher V, Santini J, Lecomte T, Etienne-Grimaldi MC, Paintaud G, Milano G. J Clin Oncol. 2008 Sep 1;26(25):4223-5.